Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Assets Average (2016 - 2026)

Heron Therapeutics filings provide 15 years of Assets Average readings, the most recent being $251.0 million for Q1 2026.

  • On a quarterly basis, Assets Average rose 7.08% to $251.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $251.0 million, a 7.08% increase, with the full-year FY2025 number at $244.5 million, up 7.32% from a year prior.
  • Assets Average hit $251.0 million in Q1 2026 for Heron Therapeutics, down from $252.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $289.7 million in Q1 2022 to a low of $211.1 million in Q2 2023.
  • Median Assets Average over the past 5 years was $234.4 million (2025), compared with a mean of $238.4 million.
  • Biggest five-year swings in Assets Average: plummeted 31.81% in 2022 and later grew 11.21% in 2025.
  • Heron Therapeutics' Assets Average stood at $261.5 million in 2022, then dropped by 13.62% to $225.9 million in 2023, then increased by 0.49% to $227.0 million in 2024, then rose by 11.21% to $252.4 million in 2025, then decreased by 0.54% to $251.0 million in 2026.
  • The last three reported values for Assets Average were $251.0 million (Q1 2026), $252.4 million (Q4 2025), and $240.5 million (Q3 2025) per Business Quant data.